OTCM
PURE
Market cap10mUSD
Oct 08, Last price
0.08USD
1D
-2.16%
1Q
32.69%
Jan 2017
-90.46%
Name
PURE Biosciences Inc
Chart & performance
P/E
—
P/S
4.91
EPS
—
Div yield, %
—
Shrs. gr., 5y
5.74%
Rev. gr., 5y
-20.46%
Revenues
2m
+12.18%
Net income
-2m
L-28.39%
CFO
-2m
L-20.39%
Notes
No notes on this company yet
Write a private note on this company, for your eyes only
Profile
PURE Bioscience, Inc. develops and commercializes antimicrobial products that provide solutions to the health and environmental challenges of pathogen and hygienic control in the United States and internationally. The company’s technology platform contains silver dihydrogen citrate (SDC), a non-toxic antimicrobial agent, which offers residual protection, as well as formulates with other compounds. It offers SDC-based disinfecting and sanitizing products, including PURE Hard Surface, a ready-to-use hard surface disinfectant and food contact surface sanitizer and disinfectant; PURE Control, eliminates pathogens in produce, such as salmonella, e. coli, and listeria; PURE Multi-Purpose Hi-Foam Floor Cleaner Concentrate, a cleaning product for stainless steel, floors, walls, and painted areas; PURE Multi-Purpose Floor Cleaner, for sanitation in food processing plants, commercial kitchens, healthcare facilities, schools, and hospitality settings; and SILVERION, a SDC-based antimicrobial formulation for use as a raw material ingredient in the manufacturing of personal care products. The company serves food processing, food service and hospitality, healthcare, facility care, transportation, and personal care industries. It sells its products through end-use customers and third-party distributors. The company was incorporated in 1992 and is based in El Cajon, California.
Key people
Ivan Chen
Independent Chairman of the Board · since 2021
Mark Elliott
Principal Financial Officer, Principal Accounting Officer, Vice President - Finance · since 2020
Jeffrey Kitchell
President, Corporate Secretary · since 2025
Robert Bartlett
Chief Executive Officer, Principal Executive Officer, Director · since 2025
Tom Lee
Director · since 2023
Tom Myers
Executive Vice President - Technology and Development, Director · since 2023
Bernard Blotner
Independent Director · since 2023
David Rendall
Independent Director · since 2021
Darin Zehr
Independent Director · since 2024
Valuation
Title USD in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|---|---|---|---|
| 2025‑07 | 2024‑07 | 2023‑07 | 2022‑07 | 2021‑07 | 2020‑07 | 2019‑07 | 2018‑07 | 2017‑07 | |
| Income | |||||||||
Revenues | |||||||||
Cost of revenue | |||||||||
Unusual Expense (Income) | |||||||||
NOPBT | |||||||||
NOPBT Margin | |||||||||
Operating Taxes | |||||||||
Tax Rate | |||||||||
NOPAT | |||||||||
Net income | |||||||||
Dividends | |||||||||
Dividend yield | |||||||||
Proceeds from repurchase of equity | |||||||||
BB yield | |||||||||
| Debt | |||||||||
Debt current | |||||||||
Long-term debt | |||||||||
Deferred revenue | |||||||||
Other long-term liabilities | |||||||||
Net debt | |||||||||
| Cash flow | |||||||||
Cash from operating activities | |||||||||
CAPEX | |||||||||
Cash from investing activities | |||||||||
Cash from financing activities | |||||||||
FCF | |||||||||
| Balance | |||||||||
Cash | |||||||||
Long term investments | |||||||||
Excess cash | |||||||||
Stockholders' equity | |||||||||
Invested Capital | |||||||||
ROIC | |||||||||
ROCE | |||||||||
| EV | |||||||||
Common stock shares outstanding | |||||||||
Price | |||||||||
Market cap | |||||||||
EV | |||||||||
EBITDA | |||||||||
EV/EBITDA | |||||||||
Interest | |||||||||
Interest/NOPBT | |||||||||